Cyxone AB (publ) (CYXO.ST) Research

Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.

Market snapshot

Symbol
CYXO.ST
Price
$0.02
Day change
0.00%
Market cap
$6.8M
P/E ratio
-0.08x
52-week range
0.01-0.161
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Asarina Pharma AB (publ) (ASAP.ST)
  • Bonzun AB (publ) (BONZUN.ST)
  • Cline Scientific AB (publ) (CLINE-B.ST)
  • Duearity AB (publ) (DEAR.ST)
  • Hemcheck Sweden AB (publ) (HEMC.ST)
  • Idogen AB (publ) (IDOGEN.ST)
  • Pharmiva AB (publ) (PHARM.ST)
  • Redwood Pharma AB (REDW.ST)

Open Cyxone AB (publ) (CYXO.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.